Benzinga | Jul 1, 2021 01:41PM EDT

Precision BioSciences Starts Dosing In Blood Cancer Trial With CAR T Therapy

* Precision BioSciences Inc (NASDAQ:DTIL) has dosed the first patient in its Phase 1 trial with PBCAR19B in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL)

* PBCAR19B is an immune-evading allogeneic CAR T stealth cell candidate.

* The study's primary objective is to identify the maximum tolerated dose and any dose-limiting toxicities.

* Price Action: DTIL shares are down 0.16% at $12.50 during the market session on the last check Thursday.